Cipla Ltd.

US Food and Drug Administration (USFDA) has completed a routine cGMP inspection at Cipla’s API manufacturing facility in Virgonangar, Bengaluru. The inspection ended with 7 observations, none of which were repeat or related to data integrity. The inspection had conducted from June 15, 2019 to June 19, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.